[PDF][PDF] Alterations in T and B cell function persist in convalescent COVID-19 patients

…, SB Knight, K Wemyss, FA McClure, L Pearmain… - Med, 2021 - cell.com
Background Emerging studies indicate that some coronavirus disease 2019 (COVID-19)
patients suffer from persistent symptoms, including breathlessness and chronic fatigue; however…

[HTML][HTML] Monocyte migration profiles define disease severity in acute COVID-19 and unique features of long COVID

NA Scott, L Pearmain, SB Knight… - European …, 2023 - Eur Respiratory Soc
Background COVID-19 is associated with a dysregulated immune response but it is unclear
how immune dysfunction contributes to the chronic morbidity persisting in many COVID-19 …

SOX 9 predicts progression toward cirrhosis in patients while its loss protects against liver fibrosis

…, LJ Birchall, AF Mullan, K Su, L Pearmain… - EMBO molecular …, 2017 - embopress.org
Fibrosis and organ failure is a common endpoint for many chronic liver diseases. Much is
known about the upstream inflammatory mechanisms provoking fibrosis and downstream …

[HTML][HTML] Conventional oxygen therapy versus CPAP as a ceiling of care in ward-based patients with COVID-19: a multi-centre cohort evaluation.

…, T Gatheral, TW Felton, N Chaudhuri, L Pearmain - …, 2021 - thelancet.com
Background Continuous positive airway pressure (CPAP) therapy is commonly used for
respiratory failure due to severe COVID-19 pneumonitis, including in patients deemed not likely …

Large scale clinical trials: lessons from the COVID-19 pandemic

AR Horsley, L Pearmain, S Knight… - BMJ open …, 2022 - bmjopenrespres.bmj.com
Background The COVID-19 pandemic has presented substantial new challenges to clinical
and research teams. Our objective was to analyse the experience of investigators and …

Add-on therapy for pulmonary fibrosis, a forthcoming era with implications for practice: the BI 101550 and RELIEF trials

L Planas-Cerezales, L Fabbri, L Pearmain - Breathe, 2023 - Eur Respiratory Soc
The therapeutic landscape for idiopathic pulmonary fibrosis (IPF) and progressive fibrosing
interstitial lung disease (PFILD) is increasingly complex, with add-on antifibrotic options now …

[HTML][HTML] Rapid Generation of Pulmonary Organoids from Induced Pluripotent Stem Cells by Co-Culturing Endodermal and Mesodermal Progenitors for Pulmonary …

A Mitchell, C Yu, X Zhao, L Pearmain, R Shah… - Biomedicines, 2023 - mdpi.com
Differentiation of induced pluripotent stem cells to a range of target cell types is ubiquitous
in monolayer culture. To further improve the phenotype of the cells produced, 3D organoid …

[PDF][PDF] PAK1-dependent mechanotransduction enables myofibroblast nuclear adaptation and chromatin organization during fibrosis

E Jokl, AF Mullan, K Simpson, L Birchall, L Pearmain… - Cell reports, 2023 - cell.com
Myofibroblasts are responsible for scarring during fibrosis. The scar propagates mechanical
signals inducing a radical transformation in myofibroblast cell state and increasing …

Changes in lung epithelial cell volatile metabolite profile induced by pro-fibrotic stimulation with TGF-β1

…, K Piper-Hanley, L Pearmain… - Journal of Breath …, 2023 - iopscience.iop.org
Volatile organic compounds (VOCs) have shown promise as potential biomarkers in idiopathic
pulmonary fibrosis. Measuring VOCs in the headspace of in vitro models of lung fibrosis …

[HTML][HTML] Lessons of the month 1: salbutamol induced lactic acidosis: clinically recognised but often forgotten

L Pearmain, R Gupta, RJ Bright-Thomas - Clinical Medicine, 2020 - ncbi.nlm.nih.gov
We present the case of an 83-year-old woman, with known asthma, admitted with increasing
dyspnoea, wheeze and a productive cough. In addition to maintenance inhaled therapy, the …